Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inhibikase Therapeutics Inc. (IKT:NASDAQ), powered by AI.
Inhibikase Therapeutics Inc. is currently trading at $1.67. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Inhibikase Therapeutics Inc. on Alpha Lenz.
View Inhibikase Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Inhibikase Therapeutics Inc.'s ROE is -36.0%. Explore profitability and growth together.”
Ask for details →Inhibikase Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutics for neurodegenerative diseases and infectious diseases that impact the nervous system. The company focuses on creating innovative drugs aimed at interrupting biological pathways contributing to these diseases. Its leading programs target conditions such as Parkinson’s disease and related disorders, offering potential new treatment options for these debilitating conditions. Inhibikase Therapeutics employs a proprietary platform for drug development, emphasizing the need for precise and effective treatments. The company holds a significant position in the biopharmaceutical sector as it works towards improving healthcare options for neurological conditions. With its ongoing research and development efforts, Inhibikase Therapeutics plays a crucial role in addressing unmet medical needs, contributing to advancements in biotech and medical science.
“Inhibikase Therapeutics Inc.'s ROE is -36.0%. Explore profitability and growth together.”
Ask for details →Inhibikase Therapeutics Inc. (ticker: IKT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15 employees.
The current price is $1.67 with a P/E ratio of -x and P/B of -x.
ROE is -36.05%.